StockNews.com Initiates Coverage on Ampio Pharmaceuticals (NYSE:AMPE)

StockNews.com started coverage on shares of Ampio Pharmaceuticals (NYSE:AMPE) in a research report issued to clients and investors on Saturday. The brokerage set a “sell” rating on the stock.

Ampio Pharmaceuticals Stock Performance

Shares of NYSE:AMPE opened at $0.62 on Friday. The firm has a market capitalization of $706,800.00, a PE ratio of -0.06 and a beta of 1.95. Ampio Pharmaceuticals has a 52-week low of $0.62 and a 52-week high of $8.30. The firm has a fifty day moving average of $1.47 and a 200 day moving average of $2.10.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. boosted its position in Ampio Pharmaceuticals by 0.4% during the first quarter. BlackRock Inc. now owns 13,996,074 shares of the company’s stock valued at $6,578,000 after buying an additional 61,269 shares during the period. Vanguard Group Inc. boosted its holdings in Ampio Pharmaceuticals by 20.0% during the 3rd quarter. Vanguard Group Inc. now owns 9,954,092 shares of the company’s stock valued at $602,000 after acquiring an additional 1,662,127 shares during the period. State Street Corp grew its position in Ampio Pharmaceuticals by 2.0% during the 1st quarter. State Street Corp now owns 3,430,770 shares of the company’s stock worth $1,612,000 after acquiring an additional 66,375 shares during the last quarter. Millennium Management LLC increased its stake in Ampio Pharmaceuticals by 998.6% in the 2nd quarter. Millennium Management LLC now owns 2,035,413 shares of the company’s stock worth $342,000 after purchasing an additional 1,850,138 shares during the period. Finally, Two Sigma Advisers LP lifted its position in Ampio Pharmaceuticals by 304.3% in the third quarter. Two Sigma Advisers LP now owns 432,216 shares of the company’s stock valued at $26,000 after purchasing an additional 325,300 shares during the last quarter. 5.73% of the stock is currently owned by institutional investors.

Ampio Pharmaceuticals Company Profile

Ampio Pharmaceuticals, Inc, a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.